The arrival of Retatrutide ZPHC, at a concentration of 120mg, is sparking considerable excitement within the medical community. This novel dual GIP and GLP-1 agonist medication seems to provide notable improvements in body loss compared to previous therapies. Initial clinical data have shown sign… Read More